Skip to main content
CF PharmTech, Inc. logo

CF PharmTech, Inc. — Investor Relations & Filings

Ticker · 2652 HKEX Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2026-06-10 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 2652

About CF PharmTech, Inc.

https://www.cfpharmtech.com

CF PharmTech, Inc. is a commercial-stage specialty pharmaceutical company specializing in the research, development, manufacturing, and commercialization of complex drug delivery systems, primarily focusing on inhalation technologies. The company develops treatments for major respiratory conditions, including asthma, Chronic Obstructive Pulmonary Disease (COPD), and allergic rhinitis. Its core product platforms encompass Inhalation Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), inhalation liquid preparations (nebulizers), and nasal sprays. The firm also leverages advanced formulation techniques, such as liposomes, to enhance drug efficacy and delivery.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 98% confidence The document is a Hong Kong Exchange “FF305 Next Day Disclosure Return” detailing changes in issued shares, treasury shares, on-market repurchases, and repurchase mandate particulars. It is a regulatory announcement of the company buying back its own shares. This matches the “Transaction in Own Shares” category (Code: POS).
2026-06-10 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 97% confidence The document is a statutory ‘Next Day Disclosure Return’ under the Hong Kong Stock Exchange listing rules (FF305), detailing changes in issued shares and treasury shares, including a share repurchase on-market. It is not an AGM or annual report, but a specific transaction in the company’s own shares (share buyback/treasury sales). This matches the ‘Transaction in Own Shares’ category (POS).
2026-06-09 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 97% confidence The document is a structured Next Day Disclosure Return (FF305) filed under Hong Kong Main Board/GEM Rules, detailing share repurchase transactions and treasury share changes. It provides repurchase quantities, prices, legal confirmations, and balance updates. This aligns with reporting of a company’s own share transactions (buybacks), fitting the definition of “Transaction in Own Shares.”
2026-06-05 English
VOLUNTARY ANNOUNCEMENT INHALATION FORMULATION PRODUCTION BASE PASSED GMP INSPECTION IN A PIC/S MEMBER COUNTRY
Regulatory Filings Classification · 92% confidence The document is a voluntary announcement by CF PharmTech, Inc. regarding the successful completion of a PIC/S GMP inspection for its production base. It contains no financial statements, no changes to board or management, no voting results, no capital raising or M&A activity, and no officer certifications. It is not a full report but rather a standalone operational update. This type of general regulatory/operational announcement that does not fit any specialized category falls under the fallback “Regulatory Filings” category.
2026-06-04 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return (Form FF305) under Hong Kong Exchange rules detailing changes in issued shares and treasury shares, specifically reporting on-market share repurchases and related confirmations. This precisely matches a Transaction in Own Shares report. Therefore, it should be classified as Code POS.
2026-06-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing share capital and share movement data and confirmations for the month ended 31 May 2026. It is a routine regulatory compliance submission, not an earnings release, investor presentation, or capital raising announcement. It does not itself publish financial statements but provides regulatory information on share movements. Therefore it best fits into the fallback category for general regulatory filings and disclosures (RNS).
2026-06-03 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.